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Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic
options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin
type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of
skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.Wasting of skeletal muscle is common in
a number of diseases, including sepsis,
severe injury, renal failure, diabetes, and
cancer. Muscle atrophy leads to general
muscle weakness (asthenia), impairment
of normal activities, and eventually death
through respiratory failure. Muscle loss is
part of the syndrome of cachexia and
arises through a combination of hypoa-
nabolism, together with increased catabo-
lism of myofibrillar proteins, particularly
myosin. Cachexia affects 80% of
patients with advanced cancers and
accounts for 25% of deaths, but current
treatments for muscle atrophy are limited.
Many studies show that the ubiquitin-pro-
teasomeproteolyticpathwayplaysamajor
role in the degradation of muscle proteins
during cachexia (Lecker et al., 1999).
Expression of two muscle-specific ubiqui-
tin ligases isessential for ubiquitinationand
subsequent degradation of myofibrillar
proteins. These are MuRF1, whose sub-
strates include myosin in muscle and
troponin 1 in heart (Clarke et al., 2007),
and atrogin-1/MAFbx, which targets the
eukaryotic initiation factor 3 subunit 5 that
induces expression of muscle structural
proteinsandboostsmusclegrowth (hyper-
trophy) (Lagirand-Cantaloube, et al.,
2008). Apoptosis may also be involved in
muscle wasting, and depression of protein
synthesis and stem cell quiescence are
also known to lead to hypoanabolism. In
this issue, Zhou et al. (2010) report the
identity of a new potential therapeutic tar-
get, the activin type-2 receptor (ActRIIB),
for treating muscle wasting. They show in
several mouse models of cachexia that
blocking ActRIIB with a decoy receptor
not only counters the wasting process in
skeletal muscle and heart but also is
associated with increased survival.A number of factors have been impli-
cated in muscle wasting, including cyto-
kines such as tumor necrosis factor-
a (TNF-a), interleukin-1 (IL-1) and IL-6,
and interferon-g, as well as tumor factors
such as proteolysis-inducing factor and
glucocorticoids (Tisdale, 2009). Myosta-
tin, a member of the TGF-b superfamily,
plays an important role in glucocorticoid-
induced muscle atrophy (Gilson et al.,
2007). Myostatin is a negative regulator
of muscle growth and, together with acti-
vin, another member of the TGF-b family,
is thought to be responsible for the devel-
opment of cachexia in mice lacking the
hormone inhibin (which antagonizes acti-
vin action) (Matzuk et al., 1994). Both
myostatin and activin bind to ActRIIB,
a high-affinity activin type-2 receptor in
muscle, to initiate a signaling cascade
leading to increased expression of atro-
gin-1 andMuRF1 and increased degrada-
tion of myofibrillar proteins through the
ubiquitin-proteasome pathway (Figure 1).
In the Zhou et al. (2010) study, the
authors examined the therapeutic
potential of blocking the ActRIIB pathway
on muscle wasting and survival by using
an ActRIIB decoy receptor (sActRIIB) in
several mouse models of cachexia
(Figure 1). The results obtained in these
models—which included mice trans-
planted with murine colon-26 carcinoma
cells, nude mice transplanted with human
G361 melanoma or human TOV-21G
ovarian carcinoma xenografts, and
inhibin-deficient animals—show that this
treatment not only prevents further skel-
etal muscle wasting, but also restores
previous muscle loss, although it had no
effect on fat mass. Treatment with the
sActRIIB decoy receptor also completely
blocked the atrophy of cardiac muscle,Cell 14without any change in expression of
the atrophy-specific ubiquitin ligases,
MuRF1 or atrogin-1, or stimulation of
stem cell proliferation. There was an
increase in the survival time of the treated
animals even though tumor growth was
not inhibited, reflecting the importance
of cachexia, in particular the loss of skel-
etal muscle, in determining the survival
time of cancer patients. Treatment with
sActRIIB had no effect on the production
of TNF-a, IL-1b, or IL-6, although it stimu-
lated food intake. Treatment attenuated
activation of the ubiquitin-proteasome
system, decreasing expression of both
atrogin-1 andMuRF1, as well as ubiquitin,
and increasing levels of myosin. In the
muscles of mice lacking inhibin-a,
expression of phosphorylated Smad2 is
markedly increased above levels in wild-
type animals; treatment with sActRIIB
completely blocked Smad2 phosphoryla-
tion and activation. Smad2 is a transcrip-
tion factor that stimulates activation of
FOXO3a, which is then dephosphorylated
and moves to the nucleus, where it
induces expression of both atrogin-1
and MuRF1 (Figure 1). Treatment with
sActRIIB decreased the total FOXO3a
content and increased the amount of
phosphorylated FOXO3a in the gastroc-
nemius muscle of mice lacking inhibin-a,
resulting in decreased expression of
both atrogin-1 and MuRF1. In addition,
sActRIIB markedly stimulated prolifera-
tion of muscle satellite stem cells, sug-
gesting that even in severely atrophied
muscles, some satellite cells with prolifer-
ative potential are present. Thus, muscle
wasting is counteracted by administration
of the sActRIIB decoy receptor through
a decrease in protein degradation
together with hypertrophy of the satellite2, August 20, 2010 ª2010 Elsevier Inc. 511
Figure 1. Reversing Muscle Wasting in Mice
Shown is the intracellular signaling pathway activated by the TGF-b ligands myostatin and activin A (left)
and the blocking of this pathway by a decoy receptor (right).
(Left) Myostatin and activin A bind to the activin type-2 receptor (ActRIIB), resulting in phosphorylation of
Smad2, which dephosphorylates the transcription factor FOXO3a and keeps muscle satellite stem cells
quiescent. Dephosphorylated FOXO3a then moves to the nucleus and switches on expression of the
muscle-specific ubiquitin ligases MuRF1 and atrogin-1. These ubiquitin ligases stimulate degradation of
myofibrillar proteins such as myosin by the ubiquitin-proteasome system, resulting in muscle wasting
(cachexia).
(Right) A decoy receptor, sActRIIB, blocks the action of myostatin and activin A, resulting in a decrease in
phosphorylated Smad2, an increase in satellite cell proliferation, and a decrease in MuRF1 and atrogin-1.
This results in an increase in myosin and production of new muscle, resulting in a reversal of skeletal and
cardiac muscle wasting (Zhou et al., 2010).cell population, leading to the production
of new muscle.
This approach—blockingmyostatin, ac-
tivin and other myostatin family proteins—
shows more promise than previous
attempts to treat muscle wasting. Thus,
treatment of mice bearing colon-26 tumor
cells with valproic acid, a histone deacety-
lase inhibitor that increases chromatin512 Cell 142, August 20, 2010 ª2010 Elseviecompaction and decreases gene expres-
sion, decreased myostatin levels and
increased expression of follistatin, an
inhibitor of myostatin. However, there
wasnoeffect onmuscleatrophyorexpres-
sion of the ubiquitin ligases MuRF1 and
atrogin-1 (Bonetto et al., 2009). Another
study (Benny Klimek et al., 2010), also in
the colon-26 mouse model, found thatr Inc.the histone deacetylase inhibitor trichosta-
tin A, which also induces follistatin produc-
tion, failed to preserve muscle mass.
However, it did increase muscle mass in
normal mice and in mice with muscular
dystrophy. Surprisingly,mice lackingmyo-
statin implanted with the Lewis lung carci-
noma lost more muscle mass than did
wild-type mice (Benny Klimek et al.,
2010), suggesting that a lack of myostatin
signaling fromearly stagesofdevelopment
might make muscle more susceptible to
atrophy. Despite these disappointing initial
results, administration of the activin
receptor extracellular domain/Fc fusion
protein (ACVR2B-Fc) profoundly inhibited
muscle wasting and protected adipose
stores in mice bearing both colon-26 and
Lewis lung carcinoma cells (Benny Klimek
et al., 2010). These results suggest that
blocking ligands of the myostatin family
from binding to their receptors is more
successful than other approaches.
Together with the encouraging results of
Zhou et al., these data suggest that this
may be a new therapeutic strategy for
reversing cachexia-induced muscle
wasting and prolonging survival in cancer
and other diseases.REFERENCES
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